Longer Progression-Free Survival for Durvalumab in NSCLC
Longer median progression-free survival from randomization, higher response rate with durvalumab
Median Cost of Cancer Drug Development $648.0 Million
Total revenue from sales of 10 drugs was $67.0 billion, with total R&D spending of $7.2 billion
ASBMR: Romosozumab Reduces Fracture Rate in Osteoporosis
Reduced risk of new vertebral fractures, nonvertebral fractures for romosozumab and alendronate
Statins Tied to Reduced Mortality Risk in COPD
Statin exposure associated with lower all-cause, pulmonary mortality
Vaccine-Type HPV Rates Down for Unvaccinated Young Women
Significant decrease among unvaccinated women aged 18 to 26 years from 2009-2010 to 2013-2014
Dietary Approach Effective for Laryngopharyngeal Reflux
Traditional PPI treatment approach appears no better than plant-based diet and alkaline water
Budget Cuts Threaten Research on Antimicrobial Resistance
Patient safety, international status of the U.S. as leader in combating AMR both at risk
Alendronate Effective, Safe in ‘Oldest Old’ With Prior Fracture
Alendronate treatment reduced risk of hip fracture with sustained safety
Tiotropium Effective in Mild to Moderate COPD
Daily inhaled dose tied to improvements in FEV1 compared to placebo
Clinical Oral Food Challenges Result in Few Reactions
86 percent of challenges result in no reactions; anaphylaxis absent in 98 percent
